BCL2 expression is finely tuned by a variety of environmental and endogenous stimuli and regulated at both transcriptional and post-transcriptional levels. Our previous investigations demonstrated that the BCL2 major breakpoint region (mbr) in the 3 0 -UTR upregulates reporter gene expression, which implies that this region possessed intrinsic regulatory function. However, the effect of the mbr on BCL2 expression, and the underlying regulatory mechanisms, remain to be elucidated. To assess the direct effect of the mbr on the transcriptional activity of the BCL2 gene, we employed targeted homologous recombination to establish a mbr þ /mbr À heterozygous Nalm-6 cell line and then compared the transcriptional activity and apoptotic effect on transcription between the wild type and targeted alleles. We found that deletion of the mbr significantly decreased the transcriptional activity of the corresponding allele in the mbr þ /mbr À cell. The BCL2 allele deleted of the mbr had a slower response to apoptotic stimuli than did the wild type allele. The regulatory function of the mbr was mediated through SATB1. Overexpression of SATB1 increased BCL2 expression, while knockdown of SATB1 with RNAi decreased BCL2 expression. Our results clearly indicated that the mbr could positively regulate BCL2 gene expression and this regulatory function was closely related to SATB1.
Introduction
BCL2 is a key regulator of apoptosis (Hockenbery et al., 1990) and is additionally involved in cellular growth and differentiation control (Sato et al., 1994; Chen et al., 1997; Adams et al., 1999) . Given its fundamental importance for cellular fate, BCL2 expression is finely tuned by a variety of environmental and endogenous stimuli and regulated at both transcriptional and posttranscriptional levels (Young and Korsmeyer, 1993; Miyashita et al., 1994; Heckman et al., 2000; Schiavone et al., 2000; Wu et al., 2001; Heckman et al., 2002; Donnini et al., 2004) . At the transcriptional level the expression of the BCL2 gene is regulated by both positive and negative elements located within both the promoter and coding regions (Chen and Boxer, 1995; Wilson et al., 1996; Perillo et al., 2000; Lang et al., 2005) . Our previous investigations demonstrated that the BCL2 major breakpoint region (mbr) in the 3 0 -UTR upregulates reporter gene expression, which implies that this region possessed intrinsic regulatory function (Zhang et al., 2006) . However, the effect of the mbr on BCL2 expression and the underlying regulatory mechanisms remain to be elucidated.
A special AT-rich sequence binding protein 1 (SATB1) binds an AT-rich region immediately downstream of the BCL2 mbr (Ramakrishnan et al., 2000) . SATB1, as a matrix attachment region (MAR)-binding protein, regulates the genes by folding chromatin into loop domains. It belongs to a class of transcriptional regulators that function as a 'landing platform' for several chromatin remodeling enzymes and hence regulates large chromatin domains (Yasui et al., 2002) . In vivo mbr binding by SATB1 strongly implicates this BCL2 region as a MAR and it may be involved in BCL2 regulation (Ramakrishnan et al., 2000) . This notion has been implied by our previous observation that overexpression of SATB1 enhances reporter gene activity (Zhang et al., 2006) .
To assess the direct effect of the mbr on the transcriptional activity of the BCL2 gene, we first employed targeted homologous recombination to establish a mbr þ /mbr À heterozygous Nalm-6 cell line. We then compared the transcriptional activity and apoptotic effect on transcription between the wild-type and targeted alleles using this cell line. We demonstrated that the mbr was a positive regulatory element for BCL2 gene expression. Deletion of the mbr significantly decreased the transcriptional activity of the corresponding allele in the mbr þ /mbr À cell. The BCL2 allele deleted of the mbr had a slower response to apoptotic stimuli than did the wild-type allele. The regulatory function of the mbr was mediated through SATB1. Overexpression of SATB1 increased BCL2 expression, while knockdown of SATB1 with RNAi decreased BCL2 expression. Our results clearly indicated that the mbr could positively regulate BCL2 gene expression and this regulatory function was closely related to SATB1.
Results
Heterozygous disruption of the BCL2 mbr by targeted homologous recombination in the Nalm-6 cell line If the BCL2 mbr serves to aggregate functionally significant regulatory complexes, we expect that deletion of this region will alter BCL2 expression. Previously, electrophoretic mobility shift assays (EMSA) and in vivo foot-printing demonstrated the presence of diverse mbrbinding proteins in all cell lines examined (DiCroce and Krontiris, 1995; Ramakrishnan et al., 2000) . To investigate the function of the BCL2 mbr, we targeted this region in the human pre-B cell line Nalm-6 by homologous recombination. Nalm-6 cells possess a number of properties that make them an ideal model system for these studies: (1) The stage of differentiation (pre-B cell) is appropriate to the timing of the t(14;18) translocation; (2) Nalm-6 cells can be efficiently targeted by homologous recombination (Grawunder et al., 1998) . (3) SATB1 is expressed at a low, but detectable level in this cell line (unpublished observation); (4) Nalm-6 cells respond with a brisk apoptotic response to a wide variety of cytotoxic agents (Tsurusawa et al., 1997; Narla et al., 2001) .
The strategy employed to delete the mbr is diagrammed in Figure 1 . Sequences 2.0-kb upstream and 2.0-kb downstream of the BCL2 mbr, identified via a search of the NCBI database, were amplified by the PCR method, subcloned into pBlueScript KS( þ ), and analysed to confirm sequence fidelity. Subsequently, a targeting vector (Tg11) was prepared in which the neomycin (neo) selectable marker, flanked by loxP sites (Figure 1a) was inserted between the DNA sequences characterized above that are homologous to the regions upstream and downstream of the BCL2 mbr (Figure 1b , mbr-up and mbr-down). Additionally, our targeting vector contained a diphtheria-toxin (DT) expression cassette intended for selection against non-homologous integration events. The 4.0-kb of incoming BCL2 sequences, which were in common with the native gene, mediated homologous recombination between the targeting vector and one of the BCL2 alleles in Nalm-6 cells. This resulted in replacement of the 279-bp mbr element containing a 37-bp AT-rich sequence and the three 15-bp translocation clusters (Figure 1b) with the neomycin gene. Stable transfectants were selected by G418 resistance (conferred by the neo-cassette) and 563 promising clones were initially selected for further analysis. Among these, two truly positive clones were distinguished from random integrants by a PCR screening assay using the primer pairs FS/RS and Tg11-F/ R-con2 that are situated outside of the homologous regions ( Figure 2a ). The expected sizes of the amplified fragments were 2.6 and 2.1-kb, respectively, and our amplification results concurred with the predicted sizes ( Figure 2b ). Sequence analysis further confirmed the homologous recombination event. Multiple sequence alignments of our targeted mbr and surrounding regions with the published BCL2 gene sequence did not detect (Figure 1b) .
Allele-specific expression of the BCL2 gene in mbr þ /mbr À heterozygous Nalm-6 cells To determine the effects of disruption of the BCL2 mbr on gene transcription, the relative expression levels of the two BCL2 alleles were analysed with real-time reverse transcription-polymerase chain reaction (RT-PCR) using allele-specific primers ( Table 1 ) that prime from sites as shown in Figure 3A . Transcription of the targeted BCL2 allele was significantly decreased when compared with expression of the wild-type allele in both of our targeted Nalm-6 clones. We initially examined bi-allelic expression from clone 1 (named Nalm-6-1), utilizing the primer pairs AF1/AR1 and AF1/AR2 (which detected expression from the targeted and wildtype alleles, respectively). The expression level of the targeted allele was around 16-fold lower than expression of the wild-type allele (DCT ¼ 33.49-29.57E4; 2 4 ¼ 16) ( Figure 3B ). This result was confirmed by PCR priming at another locale, with the primer pairs BF2/BR1 and CF2/CR2 ( Figure 3A and B). Real-time PCR analysis of clone 2 (named Nalm-6-2), with the same sets of primer pairs, further confirmed our observations that the BCL2 mbr strongly up-regulated BCL2 gene expression in Nalm-6 cells ( Figure 3B ).
Inherent differences in primer pairs (sequence, GC content, melting temperature, etc.) or template might influence PCR amplification efficiency. We thus employed a recombinant plasmid containing the regions amplified in vivo to assess the efficiency of each primer pair. Real-time PCR did not detect any significant differences in the amplification efficiency for these primers. The efficiency was comparable between primers BF2/BR1 and CF2/CR2, and between primers AF1/ AR1 and AF1/AR2 (data are not shown). These results demonstrate that the allele-specific transcriptional activity of wild-type and disrupted BCL2 alleles reflects the intrinsic property of the two alleles. 
TGGCTTCATACCACAGGTTTCCTG mbr regulates gene expression C Ma et al variations in transcriptional activity or, alternatively, due to disparate RNA stability. To distinguish these two possibilities, the transcriptional activities of wildtype and targeted BCL2 alleles were examined with nuclear run-on transcription analysis using a modified protocol with biotin-16-uridine triphosphate (UTP) (Patrone et al., 2000; Tong et al., 2005; Zhang et al., 2005) . Results of nuclear run-on assays showed that the transcriptional activity of the targeted allele was 10.3-fold lower than that of the wild-type allele, indicating the expression discrepancy of the wild-type and the targeted BCL2 alleles was mainly due to the difference in transcriptional activities between the two alleles (DCT ¼ 34.13-30.77E3.36; 2 3.36 ¼ 10.3) (Figure 4 ).
Transcriptional activity of the wild-type and targeted alleles in response to apoptotic stimuli BCL2 is a key regulator of apoptosis. To investigate whether the BCL2 mbr is involved in the response of the BCL2 gene to apoptotic stimulation, targeted Nalm-6 cells were cultured in complete medium with 10% FBS for 24 h and then serum starved for 0 h (control), 12, 18 or 48 h. RNA was isolated and analysed by real-time PCR to assess the effect of apoptosis on BCL2 transcription from the mbr deleted and wild-type alleles. As indicated in Figure 5a , transcriptional activity of the wild-type allele decreased after 12 h serum withdrawl and then increased as time progressed. However, a slight but consistent increase in transcriptional activity of the targeted allele was observed during the entire period of mbr regulates gene expression C Ma et al serum withdrawl, indicating that wild-type and targeted BCL2 alleles had significant differences in response to serum withdrawl. To confirm the above observations, cells were induced with the topoisomerase I inhibitor camptothecin, which also stimulates apoptosis . Targeted Nalm-6 cells were cultured in complete medium containing 10 mM camptothecin and cells were harvested for RNA isolation at 0, 2, 4, 6 and 8 h time point, respectively. Real-time PCR revealed again that the targeted allele had a less strong response to apoptotic stimulus ( Figure 5b ).
Increased BCL2 expression by overexpression of SATB1
It is known that the mbr is the binding site of SATB1 (Ramakrishnan et al., 2000) and our previous investigation has shown SATB1 could increase the mbr capability to upregulate reporter gene activity (Zhang et al., 2006) . To examine the contribution of SATB1 in the regulation of BCL2 gene expression, SATB1 expression plasmids or control plasmids, respectively, were transiently transfected into Nalm-6 cells that normally express low levels of SATB1. Western blot analysis showed that overexpression of SATB1 increased BCL2 expression ( Figure 6 ).
Decreased BCL2 expression by knock down of SATB1 with RNAi
To further investigate the role of SATB1 in BCL2 regulation, specific and non-specific siRNA expression plasmids were transiently transfected into Jurkat cells that normally express high levels of SATB1. Western blot analysis demonstrated that reduction of SATB1 expression resulted in decreased BCL2 expression (Figure 7 ).
Discussion
Here, we report a novel mechanism to control expression of the BCL2 gene: regulation is mediated through the BCL2 mbr, which is located within the 3 0 -UTR of the gene. Specifically, this region upregulates gene expression and increases the cellular response to apoptotic stimulation. The regulatory functions could be mediated by SATB1.
A BCL2 mbr þ /mbr À Nalm-6 cell line was established by means of homologous recombination. Out of a total of 563 G418-resistant Nalm-6 colonies screened for homologous recombination at the BCL2 locus, two positive clones were identified indicating that this gene Figure 5 Transcriptional activities of the wild type and targeted BCL2 alleles in heterozygous Nalm-6 cells following apoptosis stimulation. (a) The targeted Nalm-6 cells were cultured in complete medium with 10% FBS for 24 h followed by culturing in medium without serum for 0 h (control), 12, 18 or 48 h. Realtime reverse transcription PCR analysis was performed on purified RNA from each time point. (b) The targeted Nalm-6 cells were treated with camptothecin (10 mM) for 0 h (control), 2, 4, 6 or 8 h. Real-time reverse transcription PCR analysis was performed on purified RNA from each time point. The relative amount of the wild-type and targeted BCL2 alleles' mRNA to b-actin are shown as mean7s.d. from triplicate experiments, and the results are representative of three independent experiments. mbr regulates gene expression C Ma et al within Nalm-6 cells can be targeted successfully. Our BCL2 mbr þ /mbr À Nalm-6 cell line allowed us to directly compare the influence of the wild-type and disrupted BCL2 mbr regions on gene expression and apoptosis induction within an identical cellular milieu.
Deletion of the BCL2 mbr by homologous recombination resulted in a 16-fold decrease in BCL2 transcript levels as detected by real-time PCR. As the mRNA level of a specific gene is determined by a balance between new transcription and mRNA decay, we used the nuclear run-on assays to test the contribution resulting primarily from transcription. Nuclear run-on assays revealed that the transcriptional activity of the targeted allele was 10.3-fold lower than that of the wild-type allele, indicating that transcription is a major factor accounting for the expression discrepancy of the wildtype and the targeted BCL2 alleles.
The regulatory function of the mbr observed in our experiments could be mediated through a number of diverse mechanisms including MAR-dependent modulation of chromatin structure or alterations in localized DNA structure. Within the cellular context, actively transcribed genes are present in chromatin loop domains that function to insulate and regulate a given transcription unit independently of adjacent genes. These loop domains are anchored to the nuclear matrix via MAR elements. Loops could conceivably bring together normally distinct regulatory regions (i.e., 5 0 promoters and 3 0 enhancers, etc). The AT-rich sequence immediately downstream of the mbr is a MAR element that binds the tissue-specific SATB1 in Jurkat cells (Ramakrishnan et al., 2000) . SATB1 regulates expression of multiple genes during development and also sequesters chromatin remodeling proteins and transcription factors to MAR elements (Alvarez et al., 2000; Yasui et al., 2002) . This MAR-binding protein is present at low levels in pre-B cells (Nalm-6) and, given its propensity to associate within the minor groove of AT-rich DNA rather than at specific sequences (Dickinson et al., 1992) , and the fact that BCL2 is transcriptionally active (open chromatin structure) in Nalm-6 cells, SATB1 likely binds the BCL2 MAR. It is possible that the mbr regulates the BCL2 gene by forming a special chromatin structure where it sequesters many regulatory proteins required for the apoptotic response, including SATB1. In this study, the level of expression of SATB1 correlated directly with that of BCL2 as shown by our SATB1 overexpression study ( Figure 6 ) and SATB1 RNAi analysis (Figure 7) . These data strongly implied that the regulatory function of the BCL2 mbr could be mediated by MAR-dependent modulation of chromatin structure.
Alternatively, non-B DNA has been implicated in regulation of gene expression (Delic et al., 1991; van Holde and Zlatanova, 1994) . The BCL2 mbr forms triplex DNA under physiological conditions and this non-B DNA is a critical structure for cleavage within the BCL2 mbr that leads to the t(14;18) translocation (Raghavan et al., 2005) . Triplex DNA can modulate gene expression both in vivo and when placed upstream of a reporter gene (Kohwi and Kohwi-Shigematsu, 1991; Grigoriev et al., 1992; Kato and Shimizu, 1992) . However, the BCL2 mbr, located within the 3 0 -UTR of the gene, is approximately 200-kb downstream from the promoter. It is therefore unlikely that the triplex DNA structure at the BCL2 locus affects upstream transcription. However, triplex DNA may in part explain our previous results in which we noted increased reporter gene activity in Jurkat cells subsequent to insertion of the mbr upstream of the luciferase gene (Zhang et al., 2006) .
The decrease in cellular BCL2 mRNA levels in response to apoptotic stimuli has been well documented, but its mechanism remains unknown Suzuki et al., 1996) . Considering that the mbr within the BCL2 3
0 -UTR appears to be endowed with transcriptional activity, we assume that it might be required for BCL2 transcriptional regulation during apoptosis. The results of our serum withdrawal assays and camptothecin treatment support this notion, as both experiments demonstrated that the targeted BCL2 allele had a lesser response to apoptotic stimulus than that of the wild-type allele. This indicates that the mbr is required for BCL2 downregulation in response to apoptotic stimuli.
Recent studies have implicated disrupted expression of BCL2 in a wide variety of human cancers, including breast, pancreas, colorectal, lung, prostate, gastric, renal, neuroblastoma, and both acute and chronic leukemias. Diverse mechanisms are likely to account for the dysregulation of BCL2 gene expression in these different neoplasms. Such variable functions could be mediated through the BCL2 mbr region. Recognition of the mbr as a new element for upregulation of the BCL2 Figure 6 SATB1 overexpression increases the expression of BCL2 in Nalm-6 cells. Nalm-6 cells were transiently transfected with empty plasmid pRGFP-C1 (lanes 1-2) or SATB1 expression plasmids pEGFP-C1-SATB1 (lanes 3-4). Cells were harvested 48 h after transfection and Western blot analysis was performed using a polyclonal anti-SATB1 serum or anti-BCL2 monoclonal antibody. b-Actin levels served as internal control.
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1 2 Figure 7 Knock down of SATB1 by RNAi decreases the expression of BCL2. Jurkat cells that express high level of SATB1 were transiently transfected with control plasmids (lane 1) or SATB1 RNAi plasmids (lane 2) using an electroporator. The cells were harvested 48 h after transfection and Western blot analysis was performed using anti-SATB1 serum or anti-BCL2 monoclonal antibody. b-Actin levels served as internal control.
mbr regulates gene expression C Ma et al gene provides an excellent and perhaps unique opportunity to study the interplay of protein interactions and DNA sequence determinants in the function of a MAR associated with a locus critical for programmed cell death and carcinogenesis.
Materials and methods
Cell culture
The pre-B Nalm-6 cells and Jurkat T-cells were cultured at densities between 0.2 and 1.0 Â 10 6 cells/ml in RPMI 1640 medium supplemented with 10% fetal calf serum (FCS), 100 U of penicillin/streptomycin per ml, and 1 mM sodium pyruvate. Cells were kept at 371C and 5% CO 2 in air in a humidified incubator.
Construction of the BCL2 targeting vector
The targeting vector, Tg11 contains the neomycin gene cassette (Neo) and the diphtheria toxin gene (DT, a generous gift from Lily Hsu at the City of Hope National Medical Center in Los Angeles, CA, USA) ( Figure 1a) . A 2.0-kb genomic BCL2 fragment from just distal to the BCL2 mbr was excised and, after addition of XbaI restriction enzyme linkers, was inserted as the 3 0 arm of the vector. Another 2.0-kb genomic fragment containing the sequence upstream of the BCL2 mbr was prepared with KpnI and HindIII restriction enzyme sites (5 0 and 3 0 ends, respectively) and inserted as the 5 0 arm. This replaces the 279-bp mbr with the selective neomycin gene (Figure 1b) . The fidelity of the cloned fragments was confirmed by sequence analysis.
Generation of mbr
þ /mbr À heterozygous Nalm-6 cells For each transfection, the targeting vector (20 mg) linearized with NotI, was transfected into 10 7 Nalm-6 cells at 300 V, 275 mF in 0.4 cm cuvette. Cells were allowed to recover in complete RPMI-1640 media for 48 h after transfection and then individual, stably transfected cell clones were selected by growth in microtiter plates for 3-5 weeks in complete RPMI-1640 media (see below) supplemented with 1.0 mg/ml G418. From six transfections, 563 clones were screened with PCR by the primers located outside the homologous regions: Tg11-F(5 0 -TATATTAAGGGTTCCGGATCGATC-3 0 )/R-con2(5 0 -C AACCTTGTTGTTGATAGGATG-3 0 ). Two positive clones were identified and checked further by PCR analysis using the primers FS(5 0 -CATGCGGCCTCTGTTTGATTTC-3 0 )/RS(5 0 -GGAGGATTGGGAAGACAATAG-3 0 ). Sequence analysis confirmed the correct homologous recombination events. Multiple alignments were performed using ClustalW 8.1 (http:// dot.imgen.bcm.tmc.edu:9331/multi-align/multi-align.html).
Allele-specific transcriptional analysis of targeted clones Transcription from the targeted and wild-type alleles was investigated by real-time RT-PCR analysis. First, primers based on the sequences of the wild-type and the targeted BCL2 alleles were designed using Primer Express 2.0 Software (ABI). Then, total RNA was isolated with Trizol reagent (Invitrogen) according to the manufacturer's protocol. The RNA was digested with RQ1 RNase-Free DNase (Promega) for 30 min to remove genomic contaminants. Subsequently, DNase was removed with the RNeasy Mini Kit (Qiagen) and absence of residual DNase was confirmed by PCR analysis. Visualizing the ribosomal bands on a 1% TAE agarose gel assessed RNA integrity. Finally, cDNA was synthesized from total RNA (1 mg) using AMV Reverse Transcriptase according to the manufacturer's instructions (Promega), and oligo(dT) 15 as the primer. The reactions were incubated at 421C for 60 min and then stored at À201C prior to use.
Real-time PCR was performed with Chromo 4 Continuous Fluorescence Detector (MJ Research). The reaction (20 ml) contained the cDNA from above, forward and reverse primers, and SYBR GREEN PCR Master Mix (Applied Biosystems, Foster City, CA, USA). Amplification conditions were 501C for 2 min, 951C for 10 min, followed by 45 cycles of denaturation at 951C for 30 s, annealing at 561C for 30 s, and extension at 721C for 30 s. Differences in expression of the wild-type BCL2 allele and the targeted allele were calculated through the comparative threshold cycle (CT) method (See details on ABI User Bulletin).
Nuclear run-on assay The transcriptional activity of wild type and of targeted BCL2 alleles was determined by nuclear run-on transcription analysis according to a modified protocol that uses biotin-16-uridine triphosphate (UTP) (Roche, Sandhofer Strasse, Mannheim, Germany) (Patrone et al., 2000; Tong et al., 2005; Zhang et al., 2005) . Briefly, 2-3 Â 10 7 Nalm6-1 cells were washed twice with ice-cold PBS and resuspended in cell lysis buffer containing 10 mM Tris-HCl (pH 7.4), 3 mM MgCl 2 , 10 mM NaCl, 150 mM sucrose and 0.5% NP-40. The isolated nuclei were gently washed with cell lysis buffer devoid of NP-40 and collected by centrifugation. The nuclei were stored frozen in 40% glycerol at À701C until used. The run-on reaction was carried out in a 2 Â transcription buffer containing 300 mM KCl, 10 mM TrisHCl, pH 8.0, 5 mM MgCl 2 , 2.5 mM each of ATP, GTP and CTP. The reaction was initiated with the addition of 2.5 mM biotin-16-UTP and incubated for 45 min at 301C. The RNA was isolated with Trizol reagent (Invitrogen) according to the manufacturer's protocol. Streptavidin particle beads (Qiagen) were used to isolate the biotin-labeled run-on RNA according to the manufacturer's protocol. The beads were resuspended in RNase-free water and stored at À201C until used. Reverse transcription and real-time PCR were performed as described above.
Analysis of transcriptional activities of the BCL2 alleles in mbr þ /mbr À heterozygous Nalm-6 cells following apoptotic stimulation To compare transcriptional activity of the wild-type and targeted BCL2 alleles after different apoptotic stimulation, the mbr þ /mbr À heterozygous Nalm-6 cells were cultivated in serum-free medium for 12, 18, or 48 h and subsequently harvested for RNA isolation and real-time PCR analysis as described above. In addition, the mbr þ /mbr À heterozygous Nalm-6 cells were treated with camptothecin at the concentration of 10 mM for 2, 4, 6 and 8 h and subsequently harvested for RNA isolation and real-time PCR analysis as described above. The levels of b-actin were determined simultaneously as an internal control. The primers of b-actin were as follow: actinup: 5 0 -CCCAGAGCAAGAGAGGCATC-3 0 ; actin-down: 5 0 -CATGATCTGGGTCATCATCTTCTCG-3 0 .
SATB1 overexpression in Nalm-6 cells To explore the effect of transcription factor SATB1 on BCL2 expression, Nalm-6 cells were transiently transfected with SATB1 overexpression plasmid pEGFP-C1-SATB1 using an electroporator, as described above. Empty plasmid pEGFP-C1 (generous gifts from Dr Krontiris' laboratory) was used as control. Transfected cells were harvested, after 48 h, for Western blot analysis of SATB1, BCL2, and actin (control) protein expression.
mbr regulates gene expression C Ma et al Knock down SATB1 by RNAi in Jurkat cells SATB1 specific and non-specific siRNA sequences were synthesized by GeneChem Corp. and inserted into the pGCsi-H1/Neo/GFP/siNEGative vector (Genscript), which coexpresses GFP to allow identification of transfection efficiency. The SATB1 shRNA comprised of: 5 0 -GCTGAAA GAGACCGAATATTTCAAGAGAATATTCGGTCTCTTT CAGC-3 0 . The non-specific shRNA sequences were: 5 0 -ACG TGACACGTTCGGAGAATTCAAGAGATTCTCCGAAC GTGTCACGT. Jurkat cells were transiently transfected with SATB1 RNAi plasmids or control plasmids using an electroporator, respectively. The transfection efficiency was 40-60%, as determined by counting of GFP-expressing cells 48 h after transfection. The extent of siRNA mediated inhibition of SATB1 and it's effect on BCL2 expression was evaluated by Western blot analysis with specific antibodies.
Western blot analysis
Whole cell extracts were prepared from cells (treated as described above) by lysis in 1 ml lysis buffer (50 mM Tris, pH7.4, 0.5% NP-40 and 0.01% SDS) containing protease inhibitors. Total protein (20 mg) was boiled for 5 min in 1 Â loading buffer, chilled on ice and then separated on 12% sodium dodecyl sulfate (SDS)-polyacrylamide gels. Subsequent to transfer onto PVDF membranes (Bio-Rad, Hercules, CA, USA), non-specific protein interactions were blocked by incubation in 5% nonfat dry milk in TSTbuffer (50 mM Tris-HCl, 150 mM NaCl, 0.05% Tween 20 pH7.6) at 41C for 1 h. Membranes were then incubated at 41C overnight with polyclonal anti-SATB1 serum, anti-BCL2 (Santa Cruz Biotechnology, Santa Cruz, CA, USA) or antib-actin monoclonal antibody (Sigma Chemical Co., St Louis, MO, USA) in fresh blocking buffer. Unbound antibody was removed by four 10 min washes in TST buffer. Membranes were then incubated with horseradish peroxide -conjugated individual secondary antibody (R&D Systems Inc., Minneapolis, MN, USA) for 1 h at room temperature followed by four 10 min washes with TST buffer. The blot was developed with ECL reagent (Amersham Biosciences, Piscataway, NJ, USA). Prestained markers (NEB) were used as internal molecular weight standards.
Abbreviations mbr, major breakpoint region; SATB1, special AT-rich sequence-binding protein 1; MAR, matrix attachment region; CRE, cAMP responsive element; NF-kB, nuclear factor-kappa B; UTR, untranslated region; EMSA, electrophoretic mobility shift assay; DT, diphtheria-toxin.
